Navigation Links
The European Alcohol Addiction Market is Poised For a Treatment Paradigm Shift With the Launch of BioTie/Lundbeck's Selincro
Date:5/9/2013

BURLINGTON, Mass., May 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European psychiatrists and U.S. managed care organization (MCO) pharmacy directors agree that a therapy's ability to support abstinence is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in the treatment of alcohol addiction. Historically, therapies for alcohol addiction have been indicated for the support of abstinence—however, BioTie/Lundbeck's Selincro recently received approval from the European Medicines Agency for reducing alcohol consumption in adult alcohol-dependent patients who have a high level of alcohol consumption, and marketers are hopeful that physicians will accept harm reduction as a meaningful treatment goal in Europe.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Alcohol Addiction: How Would a Harm Reduction Treatment Paradigm Be Received by Physicians? also finds that surveyed U.S. psychiatrists indicated that they would prescribe Alkermes' samidophan to 25 percent of their patients with alcohol addiction, if it were to proceed in development and launch for alcohol addiction in the United States.

The findings also reveal that surveyed U.S. and European psychiatrists and U.S. MCO pharmacy directors indicate that improved abstinence from alcohol is one of greatest unmet needs in alcohol addiction. However, clinical data and the opinions of interviewed thought leaders indicate that no emerging therapy has yet demonstrated the potential to fulfill this unmet need.

"The market for alcohol addiction therapies remains very small despite the relatively high prevalence of the disease because of low diagnosis and drug treatment rates," said Decision Resources Analyst Natalie Taylor , Ph.D. "Psychiatrists perceive current therapies as having limited efficacy, further dissuading them from treating patients with pharmacotherapy. The launch of Selincro may yet change the treatment paradigm of alcohol addiction—at least in Europe—by providing patients with a therapy that can be taken on an as needed basis. European thought-leaders indicate that this harm reduction model, while not representing patient abstinence, is still a meaningful treatment goal."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... As ... Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland ...
Breaking Medicine News(10 mins):